Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01102257 · ClinicalTrials.gov registry record · Phase 2

Dry Eye Assessment and Management: Feasibility Study

A Phase 2 study of Dry Eye Syndromes and Keratoconjunctivitis Sicca, sponsored by Asbell, Penny, M.D..

Completed
Registry status
Phase 2
Development phase
23
Enrollment target
1
Study location

NCT01102257: Completed Phase 2 study of Dry Eye Syndromes and Keratoconjunctivitis Sicca, sponsored by Asbell, Penny, M.D..

NCT01102257 is a Phase 2 study of Dry Eye Syndromes and Keratoconjunctivitis Sicca that has completed, run by Asbell, Penny, M.D.. The registered enrollment target is 23 participants, below the 413-participant average among 17 other Dry Eye Syndromes trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01102257, a Phase 2 study of Dry Eye Syndromes and Keratoconjunctivitis Sicca, has completed, sponsored by Asbell, Penny, M.D..

COMPLETED
Registry status
Phase 2
Development phase
23 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to test a protocol investigating the efficacy of omega-3 fatty acids in treating dry eye disease. The study is termed "feasibility" because its purpose is to demonstrate an ability to execute the proposed protocol with compliance at two sites rather than generate statistically relevant data concerning the safety and efficacy of the supplement in patients with dry eye disease.

Interventions

  • DRUG Olive Oil
  • DRUG Omega-3 EFA Supplement

Study Locations (1)

New York

  • Mount Sinai School of Medicine - New York

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2010-01
Est. Completion 2011-03
Phase Phase 2
Asbell, Penny, M.D.

1 total trials

What the finished NCT01102257 record still lists

NCT01102257 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 413-participant average among 17 other Dry Eye Syndromes trials with a reported enrollment target (94% lower).

The record links to 2 conditions, with Dry Eye Syndromes appearing as the primary indexed condition, and to 2 interventions - of which Olive Oil is the first listed.

NCT01102257 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT01102257 about?

NCT01102257 is a clinical study titled "Dry Eye Assessment and Management: Feasibility Study". The purpose of this study is to test a protocol investigating the efficacy of omega-3 fatty acids in treating dry eye disease. The study is termed "feasibility" because its purpose is to demonstrate an ability to execute the proposed protocol with compliance at two sites rather than generate statist...

What is the current status of trial NCT01102257?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2010-01. Estimated completion is 2011-03.

What conditions does trial NCT01102257 study?

This clinical trial studies the following conditions: Dry Eye Syndromes, Keratoconjunctivitis Sicca.

What interventions are being tested in trial NCT01102257?

The interventions under investigation include: Olive Oil (DRUG), Omega-3 EFA Supplement (DRUG).

Who is sponsoring clinical trial NCT01102257?

This trial is sponsored by Asbell, Penny, M.D., which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01102257 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Dry Eye Syndromes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01102257's enrollment target sits among peer trials

23 15th of 17 higher than 3 of 17 other Dry Eye Syndromes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Dry Eye Syndromes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03616041 · 23 participants

    Capsule Endoscopy for Severe Hematochezia

  • NCT04348747 · 23 participants · Phase 2

    Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

  • NCT04587687 · 23 participants · Phase 2

    Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

  • NCT04715022 · 23 participants · Phase 1

    Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01102257, the US trial registry maintained by the National Library of Medicine. NCT01102257 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.